BACKGROUND: Type 2 diabetes mellitus (T2DM) and class I obesity, which are pandemics of considerable socioeconomic importance, require new treatment modalities due to inadequate control through normal clinical conduct. The aim of the present study was to assess the efficacy and safety of Roux-en-Y gastric bypass (RYGB) in the control of T2DM in patients with a body mass index (BMI) of 30 to 35 kg/m(2). METHODS: An observational, retrospective study was carried out at the Universidade Federal de Pernambuco-Brazil. Between 2002 and 2008, 27 patients were submitted to RYGB for the treatment of uncontrolled T2DM, with a mean follow-up period of 20 months. An assessment was performed of the complete resolution of T2DM [HbA(1c) < 6%/fasting plasma glucose (FPG) < 100 mg/dL/no diabetes medication] and glycemic control. The ethics committee of the university approved the study. RESULTS: RYGB led to the following results: (1) 23% weight reduction (p < 0.001), BMI stabilized at 25.6 kg/m(2) in a mean of 12 months; (2) 46% reduction in glycemia and 27% reduction in HbA(1c) (p < 0.001); (3) 100% improvement in glycemia and 48% resolution of T2DM; (4) glycemic control was 74% without medication and 93% with medication and five patients required medication in addition to RYGB; (5) mean current FPG is 93 mg/dL and HbA(1c) is 6%; and (6) there were no severe complications or deaths. CONCLUSIONS: RYGB is a safe and effective option in the treatment of uncompensated T2DM associated to class I obesity.
BACKGROUND:Type 2 diabetes mellitus (T2DM) and class I obesity, which are pandemics of considerable socioeconomic importance, require new treatment modalities due to inadequate control through normal clinical conduct. The aim of the present study was to assess the efficacy and safety of Roux-en-Y gastric bypass (RYGB) in the control of T2DM in patients with a body mass index (BMI) of 30 to 35 kg/m(2). METHODS: An observational, retrospective study was carried out at the Universidade Federal de Pernambuco-Brazil. Between 2002 and 2008, 27 patients were submitted to RYGB for the treatment of uncontrolled T2DM, with a mean follow-up period of 20 months. An assessment was performed of the complete resolution of T2DM [HbA(1c) < 6%/fasting plasma glucose (FPG) < 100 mg/dL/no diabetes medication] and glycemic control. The ethics committee of the university approved the study. RESULTS: RYGB led to the following results: (1) 23% weight reduction (p < 0.001), BMI stabilized at 25.6 kg/m(2) in a mean of 12 months; (2) 46% reduction in glycemia and 27% reduction in HbA(1c) (p < 0.001); (3) 100% improvement in glycemia and 48% resolution of T2DM; (4) glycemic control was 74% without medication and 93% with medication and five patients required medication in addition to RYGB; (5) mean current FPG is 93 mg/dL and HbA(1c) is 6%; and (6) there were no severe complications or deaths. CONCLUSIONS: RYGB is a safe and effective option in the treatment of uncompensated T2DM associated to class I obesity.
Authors: Helena W Rodbard; Lawrence Blonde; Susan S Braithwaite; Elise M Brett; Rhoda H Cobin; Yehuda Handelsman; Richard Hellman; Paul S Jellinger; Lois G Jovanovic; Philip Levy; Jeffrey I Mechanick; Farhad Zangeneh Journal: Endocr Pract Date: 2007 May-Jun Impact factor: 3.443
Authors: Francesco Rubino; Antonello Forgione; David E Cummings; Michel Vix; Donatella Gnuli; Geltrude Mingrone; Marco Castagneto; Jacques Marescaux Journal: Ann Surg Date: 2006-11 Impact factor: 12.969
Authors: Paul E O'Brien; John B Dixon; Cheryl Laurie; Stewart Skinner; Joe Proietto; John McNeil; Boyd Strauss; Sharon Marks; Linda Schachter; Leon Chapman; Margaret Anderson Journal: Ann Intern Med Date: 2006-05-02 Impact factor: 25.391
Authors: Almino C Ramos; Manoel P Galvão Neto; Yglésio Moyses de Souza; Manoela Galvão; Abel H Murakami; Andrey C Silva; Edwin G Canseco; Raúl Santamaría; Trino A Zambrano Journal: Obes Surg Date: 2008-11-06 Impact factor: 4.129
Authors: Bennett L Parnes; Deborah S Main; L Miriam Dickinson; Linda Niebauer; Sherry Holcomb; John M Westfall; Wilson D Pace Journal: Diabetes Care Date: 2004-01 Impact factor: 19.112
Authors: Luca Busetto; John Dixon; Maurizio De Luca; Scott Shikora; Walter Pories; Luigi Angrisani Journal: Obes Surg Date: 2014-04 Impact factor: 4.129